Table 1 |
|||||
|
Comparison of clinical characteristics of patients in each group |
|||||
|
Characteristics |
Group 1 PAH |
Group 2 At risk |
Group 3 ILD |
Group 4 Controls |
P value |
|
|
|||||
|
Number (n) |
15 |
30 |
19 |
30 |
N/A |
|
|
|||||
|
Age at onset (years) |
44.5 ± 12.9 |
51.5 ± 14.8 |
40.3 ± 15.6 |
40.6 ± 13.2 |
0.015a |
|
|
|||||
|
Age at study (years) |
63.3 ± 10.5 |
66.0 ± 11.8 |
51.1 ± 12.7 |
48.7 ± 10.1 |
< 0.0001b |
|
|
|||||
|
Disease duration (years) |
18.8 ± 13.5 |
14.5 ± 10.4 |
10.8 ± 7.9 |
7.8 ± 7.2 |
0.003c |
|
|
|||||
|
Female, n (%) |
12 (80) |
25 (83) |
14 (74) |
30 (100) |
0.04 |
|
Male, n (%) |
3 (20) |
5 (17) |
5 (26) |
0 |
|
|
|
|||||
|
Limited (n) |
13 |
28 |
6 |
23 |
< 0.0001d |
|
Diffuse (n) |
2 |
2 |
13 |
7 |
|
|
|
|||||
|
ANA, n |
14 |
27 |
17 |
30 |
0.43 |
|
Anti-Scl70, n |
1 |
3 |
10 |
5 |
0.001e |
|
Anti-cent, n |
7 |
21 |
0 |
16 |
< 0.0001f |
|
|
|||||
|
WHO FC |
|||||
|
-I |
0 |
5 |
0 |
25 |
N/A |
|
-II |
2 |
11 |
12 |
5 |
|
|
-III |
11 |
14 |
6 |
0 |
|
|
-IV |
2 |
0 |
1 |
0 |
|
|
|
|||||
|
Dis. Duration, disease duration; PAH, pulmonary arterial hypertension; WHO FC, World Health Organisation Functional Class; ANA, anti-nuclear antibody; anti-Scl70, anti- topoisomerase-1 antibody; anti-cent, anti-centromere antibody. aOlder age at SSc onset in at-risk group versus other groups. bOlder age at time of study in PAH group and at-risk groups versus others. cLonger disease duration at time of study in PAH group versus controls. dHigher proportion of patients with limited subtype in all groups except ILD. eHigher proportion of Scl-70-positive patients in ILD than other groups. fHigher proportion of centromere-positive patients in all groups compared with ILD. |
|||||
|
Thakkar et al. Arthritis Research & Therapy 2012 14:R143 doi:10.1186/ar3876 |
|||||
